Research programme: anti-PSA antibodies - Diaprost
Latest Information Update: 28 Sep 2024
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Diaprost
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Prostate-cancer in Sweden (Parenteral)
- 28 Sep 2024 No recent reports of development identified for research development in Prostate-cancer(Diagnosis) in Sweden (Parenteral)
- 24 Aug 2020 Diaprost in-licenses PSA antibodies from Memorial Sloan-Kettering Cancer Center